论文部分内容阅读
CRISPR/Cas基因编辑技术是一种强大的新技术,可以精确编辑细胞基因组。该技术在实验室应用的基础上,引入至肿瘤研究领域,成为目前肿瘤治疗研究领域的热点。肺癌的综合治疗已经进入了分子靶向时代,表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变是肺腺癌最主要、最重要的驱动基因之一,表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosinekinase inhibitors,EGFR-TKI)治疗EGFR突变肺腺癌有显著疗效,但随之而来的原发性和继发性耐药现象成为当前迫切需要解决的问题。应用CRISPR/Cas基因组编辑技术进行个性化分子手术可有效地纠正或破坏EGFR突变,从而抑制肿瘤生长和进展。随着CRISPR/Cas基因重组技术的日臻完善与成熟,分子手术方法联合传统外科手术、放疗和/或TKI靶向药物治疗必将为携带EGFR突变的肺腺癌患者带来很好的希望。
The CRISPR / Cas gene editing technology is a powerful new technology that allows precise editing of the cell genome. The technology in the laboratory based on the application of the introduction into the field of cancer research has become the current hot spot in the field of cancer treatment. The comprehensive treatment of lung cancer has entered the molecular target era. Epidermal growth factor receptor (EGFR) gene mutation is one of the most important and important driving genes in lung adenocarcinoma. Epidermal growth factor receptor tyrosinase Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has a significant effect in the treatment of lung adenocarcinoma with EGFR mutation, but the ensuing primary and secondary drug resistance has become an urgent problem to be solved . The use of CRISPR / Cas genome editing technology for personalized molecular surgery can effectively correct or destroy EGFR mutations, thereby inhibiting tumor growth and progression. As CRISPR / Cas gene recombination technology is perfected and matured, molecular surgery combined with traditional surgery, radiotherapy and / or TKI targeted drug therapy will surely bring great hope for lung adenocarcinoma patients with EGFR mutations.